Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Early Access Program for Durvalumab and Tremelimumab as First Line Treatment for Patients With Unresectable Hepatocellular Carcinoma

NCT05345678 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05345678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05345678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Early Access Program for Durvalumab and Tremelimumab as First Line Treatment for Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
AstraZeneca
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma